AMAG Pharmaceuticals Inc (AMAG)-医療機器分野:企業M&A・提携分析

◆英語タイトル:AMAG Pharmaceuticals Inc (AMAG) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011405
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in women, Feraheme (ferumoxytol) for iron deficiency anemia in adult patients with chronic kidney disease and MuGard Oral Mucoadhesive for the management of oral mucositis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers these products through direct sales and a network of distributors. It has presence in the US, Switzerland and the UK. AMAG is headquartered in Waltham, Massachusetts, the US.

AMAG Pharmaceuticals Inc (AMAG) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
AMAG Pharmaceuticals Inc, Medical Equipment, Deal Details 11
Private Equity 11
MSMB Capital Management To Acquire AMAG Pharma 11
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 12
Equity Offering 13
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 13
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 15
Debt Offering 16
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 16
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 18
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 19
Acquisition 21
AMAG Pharma Plans For Sale Of The Company 21
AMAG Pharmaceuticals Inc – Key Competitors 22
AMAG Pharmaceuticals Inc – Key Employees 23
AMAG Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Financial Announcements 27
Nov 02, 2017: AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights 27
Aug 03, 2017: AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 30
May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 34
Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 36
Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 39
Nov 03, 2016: AMAG Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 41
Aug 09, 2016: AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 43
May 03, 2016: AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results 46
Feb 17, 2016: AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 48
Jan 11, 2016: AMAG Pharmaceuticals Announces Preliminary 2015 Financial Results and Provides 2016 Financial Guidance 50
Corporate Communications 51
Aug 08, 2017: AMAG Pharmaceuticals Appoints Oscar Sanchez as Vice President of Quality 51
May 16, 2017: AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs 52
Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 53
Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 54
Dec 21, 2016: AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors 55
Sep 07, 2016: AMAG Pharmaceuticals Appoints Tony Casciano as Senior Vice President of Hematology/Oncology Sales and Marketing 56
Jul 12, 2016: AMAG Pharmaceuticals Appoints Mark Stanton as Vice President, Market Access & Corporate Accounts 57
Apr 11, 2016: AMAG Pharmaceuticals Appoints Edward Myles as Chief Financial Officer 58
Jan 04, 2016: AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer 59
Other Significant Developments 60
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
AMAG Pharmaceuticals Inc, Medical Equipment, Key Facts, 2016 2
AMAG Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Deals By Market, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
MSMB Capital Management To Acquire AMAG Pharma 11
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 12
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 13
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 15
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 16
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 18
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 19
AMAG Pharma Plans For Sale Of The Company 21
AMAG Pharmaceuticals Inc, Key Competitors 22
AMAG Pharmaceuticals Inc, Key Employees 23
AMAG Pharmaceuticals Inc, Other Locations 25
AMAG Pharmaceuticals Inc, Subsidiaries 25

★海外企業調査レポート[AMAG Pharmaceuticals Inc (AMAG)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Enmax Corporation-エネルギー分野:企業M&A・提携分析
    Summary ENMAX Corporation (ENMAX), a subsidiary of City of Calgary, is a vertically integrated energy company that generates, transmits and distributes electricity; supplies natural gas; and provides value-added services. Through its subsidiaries, the company undertakes deregulated electricity gener …
  • Kaiser Permanente
    Kaiser Permanente - Strategy, SWOT and Corporate Finance Report Summary Kaiser Permanente - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Gujarat State Electricity Corporation Ltd:発電所・企業SWOT分析
    Gujarat State Electricity Corporation Ltd – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inform …
  • Hyosung Corp (004800):企業の財務・戦略的SWOT分析
    Hyosung Corp (004800) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Manulife Financial Corporation:戦略・SWOT・企業財務分析
    Manulife Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Manulife Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Ellomay Capital Ltd (ELLO):企業の財務・戦略的SWOT分析
    Summary Ellomay Capital Ltd (Ellomay), formerly NUR Macroprinters Ltd, is an energy and infrastructure consulting company that provides renewable energy, oil and gas exploration, and clean energy solutions. The company offers renewable energy services such as installation of photovoltaic plants, man …
  • SenesTech Inc (SNES):企業の財務・戦略的SWOT分析
    SenesTech Inc (SNES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Cohera Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Cohera Medical Inc (Cohera) is a medical device company that designs and develops surgical adhesives and sealants. The company’s products include TissuGlu surgical adhesive, and Sylys surgical sealant. Its TissuGlu surgical adhesive is biocompatible for internal use, and forms a bond between …
  • Novita Healthcare Ltd (NHL):製薬・医療:M&Aディール及び事業提携情報
    Summary Novita Healthcare Ltd (Novita Healthcare), formerly Avexa Ltd is a medical technology company that focuses on the measurement and treatment of attention difficulties in early childhood. The company operates through its subsidiary The Tali technology, which is developing a tablet based softwa …
  • Unisys Corp (UIS):企業の財務・戦略的SWOT分析
    Unisys Corp (UIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • New Age Metals Inc:企業の戦略・SWOT・財務分析
    New Age Metals Inc - Strategy, SWOT and Corporate Finance Report Summary New Age Metals Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • SignPath Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary SignPath Pharma Inc (SignPath) is a developer of therapeutics based on its pure synthesized curcumin compounds. The company’s curcumin compounds acts as an anti-oxidant, anti-inflammatory and anti-cell recycling agent. It develops curcumin based products in different intravenous nanoparticle …
  • Aurora Spine Corp (ASG):医療機器:M&Aディール及び事業提携情報
    Summary Aurora Spine Corp (Aurora) is a medical equipment provider that offers surgical tools. The company offers novel solutions in the spinal implant market through a range of minimally invasive, and regenerative spinal implant technologies. It develops and distributes spinal implant products whic …
  • The Boston Beer Company, Inc.:企業の戦略・SWOT・財務分析
    The Boston Beer Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Boston Beer Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Amsted Industries Inc:企業の戦略・SWOT・財務分析
    Amsted Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Amsted Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • EDF Renewables Inc:企業の戦略的SWOT分析
    EDF Renewables Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Wincanton Plc (WIN):企業の財務・戦略的SWOT分析
    Wincanton Plc (WIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Hindustan Petroleum Corp Ltd (HINDPETRO):企業の財務・戦略的SWOT分析
    Hindustan Petroleum Corp Ltd (HINDPETRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • A&D Company Ltd (7745):企業の財務・戦略的SWOT分析
    Summary A&D Company Ltd (A&D Company) is a medical equipment company that manufactures, designs, develops, and distributes advanced measuring, controlling, monitoring, and testing instruments. The company’s products include powertrain testing systems, digital analog converter, DSP platform, model ba …
  • Dawnrays Pharmaceutical (Holdings) Ltd (2348):企業の財務・戦略的SWOT分析
    Summary Dawnrays Pharmaceutical (Holdings) Ltd (Dawnrays) is a manufacturer of cephalosporin antibiotics and specific medicines. The company provides products such as cefoperazone sodium and sulbactam sodium sterile, cefoperazone sodium sterile, ceftazidime sterile, cefixme, ceftriaxone sodium crude …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆